BACKGROUND: The outcome of 20 patients with newly diagnosed mantle-cell lymphoma (MCL) treated on a prospective trial of autologous stem-cell transplantation (ASCT) and rituximab immunotherapy was compared with the outcome of 40 matched historical control patients treated with standard combination chemotherapy. PATIENTS AND METHODS: Control patients with MCL were identified from a lymphoma database, and pairs were matched with patients receiving ASCT-rituximab for stage of disease, gender and age (+/-5 years). Only patients treated with an anthracycline- or cyclophosphamide-fludarabine-based regimen were included. RESULTS: Seventeen of 20 patients who received ASCT-rituximab remain alive in remission at a median of 30 months from diagnosis; one patient relapsed 2 years post-ASCT, and two died at 7 and 11 months post-ASCT without evidence of lymphoma. Of 40 patients treated with conventional chemotherapy, with a median follow-up of 80 months, 33 have relapsed or progressed and 29 have died. Overall (OS) and progression-free (PFS) survival were superior in patients treated with ASCT-rituximab compared with those treated with conventional chemotherapy (PFS at 3 years, 89% versus 29%, P <0.00001; OS at 3 years, 88% versus 65%, P = 0.052). CONCLUSIONS: This matched-pair analysis suggests that patients with advanced-stage MCL treated with ASCT-rituximab had statistically significantly better PFS and a trend toward better OS than patients treated with conventional chemotherapy. Longer follow-up will determine response duration and the true impact of this treatment strategy on PFS and OS.
BACKGROUND: The outcome of 20 patients with newly diagnosed mantle-cell lymphoma (MCL) treated on a prospective trial of autologous stem-cell transplantation (ASCT) and rituximab immunotherapy was compared with the outcome of 40 matched historical control patients treated with standard combination chemotherapy. PATIENTS AND METHODS: Control patients with MCL were identified from a lymphoma database, and pairs were matched with patients receiving ASCT-rituximab for stage of disease, gender and age (+/-5 years). Only patients treated with an anthracycline- or cyclophosphamide-fludarabine-based regimen were included. RESULTS: Seventeen of 20 patients who received ASCT-rituximab remain alive in remission at a median of 30 months from diagnosis; one patient relapsed 2 years post-ASCT, and two died at 7 and 11 months post-ASCT without evidence of lymphoma. Of 40 patients treated with conventional chemotherapy, with a median follow-up of 80 months, 33 have relapsed or progressed and 29 have died. Overall (OS) and progression-free (PFS) survival were superior in patients treated with ASCT-rituximab compared with those treated with conventional chemotherapy (PFS at 3 years, 89% versus 29%, P <0.00001; OS at 3 years, 88% versus 65%, P = 0.052). CONCLUSIONS: This matched-pair analysis suggests that patients with advanced-stage MCL treated with ASCT-rituximab had statistically significantly better PFS and a trend toward better OS than patients treated with conventional chemotherapy. Longer follow-up will determine response duration and the true impact of this treatment strategy on PFS and OS.
Authors: Nishitha Reddy; John P Greer; Stacey Goodman; Adetola Kassim; David S Morgan; Wichai Chinratanalab; Stephen Brandt; Brian Englehardt; Olalekan Oluwole; Madan H Jagasia; Bipin N Savani Journal: Exp Hematol Date: 2012-01-21 Impact factor: 3.084
Authors: Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull Journal: Blood Adv Date: 2021-03-23
Authors: Vaishalee P Kenkre; Walter L Long; Jens C Eickhoff; Jules H Blank; Thomas A McFarland; Wayne Bottner; Hamied Rezazedeh; Jae E Werndli; Howard H Bailey; Brad S Kahl Journal: Leuk Lymphoma Date: 2011-09
Authors: Rémy Gressin; Sylvie Caulet-Maugendre; Eric Deconinck; Olivier Tournilhac; Emmanuel Gyan; Marie Pierre Moles; Abderrazak El Yamani; Jerome Cornillon; Jean François Rossi; Steven Le Gouill; Gérard Lepeu; Ghandi Damaj; Philippe Solal Celigny; Hervé Maisonneuve; Bernadette Corront; Jean Pierre Vilque; Philippe Casassus; Thierry Lamy; Marc Colonna; Philippe Colombat Journal: Haematologica Date: 2010-03-10 Impact factor: 9.941
Authors: Brian G Till; Theodore A Gooley; Nathan Crawford; Ajay K Gopal; David G Maloney; Stephen H Petersdorf; John M Pagel; Leona Holmberg; William Bensinger; Oliver W Press Journal: Leuk Lymphoma Date: 2008-06
Authors: Nagendra K Chaturvedi; Rajkumar N Rajule; Ashima Shukla; Prakash Radhakrishnan; Gordon L Todd; Amarnath Natarajan; Julie M Vose; Shantaram S Joshi Journal: Mol Cancer Ther Date: 2013-08-20 Impact factor: 6.261